Specialty Pharmacy

Hidden payer site-of-care restrictions delay specialty infusions, driving administrative burden and patient harm—and show why transparent criteria and better coordination matter.

Subgroup data show ofatumumab sharply cuts relapses, MRI lesions, and neurodamage markers in highly active relapsing MS vs teriflunomide.

Genetic analysis links low vitamin D and earlier menarche to higher AQP4-IgG NMOSD risk, reshaping prevention and sparking calls for diverse studies.

Phase 3 FENhance trial data show CNS-penetrant BTK inhibitor fenebrutinib cuts relapses and MRI lesions in relapsing MS.

New data show ublituximab boosts MS quality of life fast and may start in 1 infusion for relapsing multiple sclerosis.

New data show cladribine tablets deliver strong relapse control and reassuring safety in older adults with relapsing multiple sclerosis, including 65 years and older.

Frexalimab shows 3-year MRI and relapse control in relapsing multiple sclerosis with stable immunity and reassuring safety.

Amid the evolving landscape of MS treatments, there is an increasing emphasis on strategic approaches to early intervention and switching therapies.

ENHANCE trial data show ublituximab-xiiy can start with a single bioequivalent infusion, easing multiple sclerosis treatment initiation.

Animal pharmacy protects both farm animals and family pets through responsible medication use, compounding, and collaboration among vets, pharmacists, and owners.

Outpatient infusion and specialty pharmacy pharmacists drive safe, cost-effective oncology and chronic-care expansion, from biosimilars to community access

A strategic framework for pharmacists to successfully appeal prior authorization denials through evidence-based documentation, proper coding, and systematic follow-up to ensure patient medication access.

The FDA approved the supplemental biologics license for the expansion of IVIG (immune globulin, intravenous) use to children 2 years and older with primary humoral immunodeficiency, enabling earlier treatment and infection protection.

CVS Specialty leaders detailed how clinical expertise, predictive analytics, and EHR connectivity are accelerating therapy starts and improving patient outcomes.

Andel's direct-to-employer model partners with Eli Lilly and other pharma companies to offer flexible, insurance-free GLP-1 access that benefits employers, patients, and manufacturers.

Advanced therapy innovations are transforming cancer care but are outpacing delivery systems and community providers with specialty pharmacy support are the key to bridging the gap.

Cardinal Health’s 2026 Advanced Therapies Report found strong provider momentum for expanding advanced therapy administration into community settings.

GoodRx CCO Laura Jensen discusses how e-commerce, GLP-1 demand, and a fragmented health care system are driving a new era of direct-to-patient, cash-based pharmacy access.

Fran Gregory, PharmD, outlines the expanding landscape of advanced therapies and the pivotal role specialty pharmacies play in bringing these complex treatments to community-based providers and patients.

In a session at the Asembia AXS26 Summit, Harry Travis discusses how AI is transforming every step of the prescription process faster than the profession is prepared for.

At AXS2026, pharmacy and health care leaders explored how AI is transforming specialty care and why standards, trust, and oversight must keep pace with innovation.

The rare disease space is an area where scientific rigor meets genuine human impact.

Combining AI-driven insights with human-first outreach can overcome the emotional and behavioral barriers driving specialty medication nonadherence.

Two studies presented at the World Congress of Nephrology 2026 highlight nonpharmacological strategies that may help preserve kidney function in at-risk populations.

Risk-based screening, early symptom recognition, and patient engagement can help pharmacists detect chronic kidney disease and prevent progression.

Kyle Fischer, PharmD, explains navigating payer hurdles, supporting adherence, and improving coordination in ILD and PAH care.

This week's episode highlights new data on the newly approved oral GLP-1, orforglipron, the growing role of sports pharmacists, and FDA approval of a higher-dose regimen for spinal muscular atrophy.